等待開盤 11-19 09:30:00 美东时间
-3.995
-1.36%
Inside Citadel's Q3 13F: Ken Griffin slashed AMD and Amazon, raised Marvell 729%, and quietly unwound Leopold Aschenbrenner's AI fund.
11-17 18:56
Four sectors are higher and seven are lower in Monday’s regular session, with defensive sectors holding the top three positions. The leaders are clustered rather than widely separated, with the top three staying within a narrow range of one another.
11-17 00:00
https://news.abbvie.com/2026-10-02-AbbVie-to-Participate-in-Federal-340B-Rebate-Model-Pilot
10-03 03:59
Three sectors are higher and eight are lower in Monday’s regular session, with defensive and cyclical sectors split across the top three positions. The leaders are separated rather than clustered.
09-28 23:05
https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
09-26 06:04
AbbVie shares gained 1.4% to close at $256.92 on Thursday while Transocean shares rose 0.4% to settle at $5.32 during the session.
07-24 19:53
REGENXBIO announced positive long-term sura-vec trial data for wet AMD and diabetic retinopathy, alongside a $100 million offering.
07-20 22:45
Genmab reports positive Phase 3 EPCORE DLBCL-4 results in relapsed lymphoma; analyst points to label expansion and future growth opportunities.
07-01 00:31
US lawmakers probe Merck and AbbVie over national security and ethical risks tied to clinical trials conducted in China.
06-30 21:13
FDA approves AbbVie Skyrizi for pediatric psoriasis, while EU’s CHMP backs Rinvoq for vitiligo and alopecia. Read the latest updates.
06-30 01:04